This week, Mike and Jeremy continue the discussion around Amylyx Pharmaceutical’s phase 2 clinical trial results of AMX0035, which was shown to slow down progression of ALS in trial participants. They are joined by Dr. Kuldip Dave, vice president of research at The ALS Association, to gain insight into how AMX0035 fits into the broader context of the ALS research landscape. They then are joined by two leaders from the ALS community, Sandy Morris and Tommy May, who share their thoughts on  why this gives the community hope, and how the petition to expedite access to AMX0035 illustrates the level of urgency in the fight.

For more information on how AMX0035 works and why it’s inspiring so much home, read https://www.als.org/stories-news/als-association-i-am-als-call-amylyx-fda-make-promising-new-drug-available-our-als

To sign and the petition calling on Amylyx Pharmaceuticals and FDA to expedite access to AMX0035 go to https://als.quorum.us/campaign/28538/

To read about Tommy May’s work to protect access to noninvasive ventilators, check out https://www.als.org/stories-news/als-association-board-member-urges-congress-protect-right-breathe

To read more about Sandy’s story, read https://iamals.org/stories/sandy-morris/

This episode was produced by Garrett Tiedemann and is brought to you by The ALS Association’s national office and the Association’s Minnesota/North Dakota/South Dakota Chapter.